GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma

Phase 1

Terminated

Conditions: Asthma

Interventions: Drug: Prednisolone
Procedure: Bronchoscopy

First Posted Date: 2006-05-18

Last Posted Date: 2017-08-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 47

Registration Number: NCT00327197

Locations: 🇬🇧
GSK Investigational Site, Leicester, Leicestershire, United Kingdom

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Phase 3

Completed

Conditions: Neisseria Meningitidis
Haemophilus Influenzae Type b

Interventions: Biological: Priorix™
Biological: Haemophilus influenzae type b and meningococcal serogroup C (vaccine)
Biological: Hiberix™
Biological: Meningitec™

First Posted Date: 2006-05-16

Last Posted Date: 2018-08-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 433

Registration Number: NCT00326118

Locations: 🇦🇺
GSK Investigational Site, Perth, Western Australia, Australia

Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

Phase 3

Completed

Conditions: Nausea and Vomiting, Postoperative

Interventions: Drug: GW679769 (casopitant)

First Posted Date: 2006-05-16

Last Posted Date: 2016-10-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 482

Registration Number: NCT00326248

Locations: 🇬🇧
GSK Investigational Site, Liverpool, United Kingdom

Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine

Phase 3

Completed

Conditions: Tetanus
Haemophilus Influenzae Type b
Diphtheria
Poliomyelitis
Acellular Pertussis

Interventions: Biological: DTPa-HBV-IPV/Hib
Biological: DTPa-IPV/Hib vaccine

First Posted Date: 2006-05-12

Last Posted Date: 2018-06-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 702

Registration Number: NCT00325143

Locations: 🇸🇬
GSK Investigational Site, Singapore, Singapore

SERETIDE Plus Tiotropium Versus Individual Components

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-05-12

Last Posted Date: 2016-10-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 41

Registration Number: NCT00325169

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants

Phase 4

Completed

Conditions: Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines
Acellular Pertussis
Haemophilus Influenzae Type b
Poliomyelitis
Diphtheria
Tetanus

Interventions: Biological: GSK Biologicals' combined DTPa-IPV/Hib vaccine

First Posted Date: 2006-05-12

Last Posted Date: 2020-01-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2590

Registration Number: NCT00325156

Locations: 🇸🇬
GSK Investigational Site, Singapore, Singapore

Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B

Phase 4

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: adefovir dipivoxil tablets

First Posted Date: 2006-05-11

Last Posted Date: 2009-10-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 533

Registration Number: NCT00324961

Locations: 🇨🇳
GSK Investigational Site, Shanghai, China

Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine

Phase 2

Completed

Conditions: Malaria

Interventions: Biological: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Biological: Hiberix®
Biological: Engerix™-B
Biological: Prevnar™
Drug: sulfadoxine-pyrimethamine
Drug: amodiaquine

First Posted Date: 2006-05-09

Last Posted Date: 2016-12-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1737

Registration Number: NCT00323622

Locations: 🇲🇿
GSK Investigational Site, Maputo, Mozambique

Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects

Phase 3

Completed

Conditions: Neisseria Meningitidis
Haemophilus Influenzae Type b

First Posted Date: 2006-05-09

Last Posted Date: 2016-09-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 468

Registration Number: NCT00323050

Locations: 🇪🇸
GSK Investigational Site, Velez, Malaga, Spain

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

Phase 3

Completed

Conditions: Haemophilus Influenzae Type b
Neisseria Meningitidis

Interventions: Biological: Haemophilus influenzae type b- and meningococcal (vaccine)
Biological: Infanrix™ penta
Biological: Meningitec™
Biological: Infanrix™ hexa
Biological: Engerix-B
Biological: NeisVac-C™
Biological: Infanrix™ IPV/HIB

First Posted Date: 2006-05-05

Last Posted Date: 2016-10-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 230

Registration Number: NCT00322335

Locations: 🇪🇸
GSK Investigational Site, Vélez-Málaga / Málaga, Spain

Home Terms & Conditions Privacy Policy